Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label Study to Evaluate Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic Human Papilloma Virus Associated Cancers

NCT03439085 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03439085
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03439085 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label Study to Evaluate Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic Human Papilloma Virus Associated Cancers
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Terminated
Start date
November 14, 2018
Completion date
September 20, 2022
Enrollment
41 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

human papillomavirus-16 positive, human papillomavirus-18 positive, metastatic malignant neoplasm, recurrent anal canal carcinoma, recurrent cervical carcinoma, recurrent malignant neoplasm, recurrent penile carcinoma, recurrent vaginal carcinoma, recurrent vulvar carcinoma, refractory malignant neoplasm, stage iv anal cancer ajcc v8, stage iv cervical cancer ajcc v8, stage iv penile cancer ajcc v8, stage iv vaginal cancer ajcc v8, stage iv vulvar cancer ajcc v8, stage iva cervical cancer ajcc v8, stage iva vaginal cancer ajcc v8, stage iva vulvar cancer ajcc v8, stage ivb cervical cancer ajcc v8, stage ivb vaginal cancer ajcc v8, stage ivb vulvar cancer ajcc v8